The PRISTINE (Pneumonia treated with RIfampicin aTtenuates INflammation) trial is a randomized, therapeutic controlled, exploratory study in patients with community-acquired pneumonia, looking at inflammatory responses during treatment with both rifampicin and b-lactam compared with treatment with b-lactam antibiotics only. The study was conducted at the Leiden University Medical Center (LUMC), a tertiary university hospital in the Netherlands. The study was approved by the LUMC Medical Ethics Committee and all patients provided written informed consent. This study was performed in compliance with the Declaration of Helsinki. The trial is registered in the Dutch trial registry, number NTR3751 (European Clinical Trials Database number 2012-003067-22). 


Section:patients and methods